Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device
19 Mar 2024
For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs)
The new training application for ICU staff combines digital learning elements with real-life training on the Fresenius Medical Care Continuous Kidney Replacement Therapy system
This learning experience reinforces initial training, a supplement to support new staff amidst the high fluctuation of specialists in intensive care nursing
BAD HOMBURG, Germany, March 19, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards. The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.
"We have a dedicated focus on leveraging advanced technology to develop and provide the most innovative technologies, engineered to facilitate and simplify the learning process. Our innovative solution is designed to ensure that nursing staff, particularly those in Intensive Care Units, are equipped with the knowledge needed to provide high-quality and exceptional patient care," says
Dr. Katarzyna Mazur-Hofsäß, member of the Management Board of Fresenius Medical Care AG and responsible for Care Enablement, Fresenius Medical Care's MedTech segment.
The AR glasses allow for self-guided, on-demand education for critical care professionals. For example, users train how to set up the machine, how to activate the citrate pump or how to handle several system components through the AR training. The AR glasses provide access to the Augmented Reality learning program
Ready4 multi
FiltratePRO
AR, which Fresenius Medical Care presented today at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.
The AR training application,
Ready4 multi
FiltratePRO
AR, will be launched in select markets as early as Q2 2024 and subsequently made available to further countries in the company's Europe, Middle East and Africa as well as Asia Pacific regions. A limited launch of the mult
iFiltratePRO will take place in the United States later this year. Upon successful completion of the Safety of Regional Citrate Anticoagulation (SARCA) trial, a full launch of the multi
FiltratePRO with the
Ready4 multi
FiltratePRO
AR learning experience is planned for 2025.
Nursing shortages in the ICU, in particular high staff turnover rates and staff taking on new tasks at short notice, are a significant concern in hospitals and healthcare systems worldwide. This training approach aims to address the challenges the industry is currently facing and to support the increasing demand for flexible, high-quality ongoing education to reinforce basic training.
Ready4 multi
FiltratePRO
AR has been specifically developed for use with the multi
FiltratePRO, Fresenius Medical Care's Continuous Kidney Replacement Therapy system. Today, the multi
FiltratePRO is used in more than 40 countries globally.
To learn more about the
Ready4 multi
FiltratePRO
AR, please visit https://www.freseniusmedicalcare.com/en/ready4-multifiltratepro-ar.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,000 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 332,000 patients around the globe and is the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release.
Media contact
Christine Peters
T +49 160 60 66 770
[email protected]
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
[email protected]
www.freseniusmedicalcare.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.